Champions Oncology, Inc. (CSBR)
NASDAQ: CSBR · Real-Time Price · USD
6.42
-0.14 (-2.21%)
Oct 10, 2025, 1:14 PM EDT - Market open

Company Description

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States.

The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.

It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies.

In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies.

It markets its products through internet and sales force to pharmaceutical and biotechnology companies.

The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011.

Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

Champions Oncology, Inc.
Champions Oncology logo
CountryUnited States
Founded1985
IPO DateMar 25, 1986
IndustryBiotechnology
SectorHealthcare
Employees213
CEORobert Brainin

Contact Details

Address:
One University Plaza, Suite 307
Hackensack, New Jersey 07601
United States
Phone201 808 8400
Websitechampionsoncology.com

Stock Details

Ticker SymbolCSBR
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearMay - April
Reporting CurrencyUSD
CIK Code0000771856
CUSIP Number15870P307
ISIN NumberUS15870P3073
Employer ID52-1401755
SIC Code2836

Key Executives

NamePosition
Robert BraininChief Executive Officer and Director
Dr. Ronnie Morris M.D.Executive Chair
David Barry Miller M.B.A.Chief Financial Officer
Dr. Maria Mancini Ph.D.Chief Operating Officer
Gavin CooperVice President of Global Marketing
Dr. Michael Ritchie M.B.A., Ph.D.Chief Commercial Officer
Dr. Marianna Zipeto Ph.D.Executive Vice President of Commercial, Research Services and Partnering

Latest SEC Filings

DateTypeTitle
Sep 15, 202510-QQuarterly Report
Sep 15, 20258-KCurrent Report
Aug 22, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Aug 22, 2025DEF 14AOther definitive proxy statements
Jul 23, 202510-KAnnual Report
Jul 23, 20258-KCurrent Report
Jul 21, 20258-KCurrent Report
Mar 17, 202510-QQuarterly Report
Mar 11, 20258-KCurrent Report
Mar 4, 2025UPLOADFiling